^
    24h
    CHIMERA: Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. (clinicaltrials.gov)
    P2, N=42, Recruiting, Gruppo Oncologico del Nord-Ovest
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CA 19-9 (Cancer antigen 19-9)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Avastin (bevacizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine
    1d
    STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, National Cancer Institute, Naples
    Trial initiation date
    |
    MSI (Microsatellite instability) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • DPYD (Dihydropyrimidine Dehydrogenase)
    |
    RAS mutation
    |
    Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • oxaliplatin • irinotecan
    1d
    ESCAPE: Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients (clinicaltrials.gov)
    P=N/A, N=66, Recruiting, Erasmus Medical Center
    Trial initiation date
    |
    Opdivo (nivolumab) • capecitabine
    1d
    GEMINI-PeriOp GC: A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=100, Recruiting, AstraZeneca
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • HER-2 negative • CLDN18.2 positive • CLDN18.2 positive + HER-2 negative
    |
    docetaxel • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    1d
    BGB-A317-316: A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=351, Recruiting, BeOne Medicines
    Trial initiation date
    |
    cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • leucovorin calcium
    1d
    ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, ALX Oncology Inc.
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • gemcitabine • paclitaxel • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • evorpacept (ALX148)
    3d
    OptiTROP Breast02: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    3d
    NOAHS-ARC: No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=39, Completed, Servicio de Salud Metropolitano Sur Oriente | Active, not recruiting --> Completed | N=73 --> 39 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion • Enrollment change • Trial primary completion date
    |
    capecitabine • oxaliplatin • leucovorin calcium
    4d
    A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults (clinicaltrials.gov)
    P2, N=49, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Focus V (anlotinib) • capecitabine • Duoenda (mitoxantrone liposomal)
    4d
    Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> Mar 2029 | Trial primary completion date: Feb 2025 --> Mar 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine
    4d
    OMEC-5: Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma (clinicaltrials.gov)
    P2/3, N=290, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026
    Enrollment open • Trial initiation date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin
    4d
    Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy (clinicaltrials.gov)
    P2, N=0, Withdrawn, Rutgers, The State University of New Jersey | N=75 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    gemcitabine • capecitabine